메뉴 건너뛰기




Volumn 18, Issue 6, 2014, Pages 599-604

Review of the Prognostic Value of Galectin-3 in Heart Failure Focusing on Clinical Utility of Repeated Testing

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GALECTIN 3;

EID: 84916892119     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-014-0113-4     Document Type: Review
Times cited : (7)

References (33)
  • 1
    • 39549100788 scopus 로고    scopus 로고
    • Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis
    • COI: 1:CAS:528:DC%2BD1cXis1ajur8%3D, PID: 18202187
    • Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008;172:288–98.
    • (2008) Am J Pathol , vol.172 , pp. 288-298
    • Henderson, N.C.1    Mackinnon, A.C.2    Farnworth, S.L.3
  • 2
    • 33645533798 scopus 로고    scopus 로고
    • Galectin-3 regulates myofibroblast activation and hepatic fibrosis
    • COI: 1:CAS:528:DC%2BD28XjsVGlsbs%3D, PID: 16549783
    • Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA. 2006;103:5060–5.
    • (2006) Proc Natl Acad Sci USA , vol.103 , pp. 5060-5065
    • Henderson, N.C.1    Mackinnon, A.C.2    Farnworth, S.L.3
  • 3
    • 84855561494 scopus 로고    scopus 로고
    • Galectin-3: a novel blood test for the evaluation and management of patients with heart failure
    • PID: 22249510
    • McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2011;12:200–10.
    • (2011) Rev Cardiovasc Med , vol.12 , pp. 200-210
    • McCullough, P.A.1    Olobatoke, A.2    Vanhecke, T.E.3
  • 5
    • 84862640503 scopus 로고    scopus 로고
    • The fibrosis marker galectin-3 and outcome in the general population
    • PID: 22026577
    • De Boer RA, van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med. 2012;272:55–64.
    • (2012) J Intern Med , vol.272 , pp. 55-64
    • De Boer, R.A.1    van Veldhuisen, D.J.2    Gansevoort, R.T.3
  • 6
    • 84866729958 scopus 로고    scopus 로고
    • Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community
    • COI: 1:CAS:528:DC%2BC38XhsVCjsb3O, PID: 22939561
    • Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60:1249–56.
    • (2012) J Am Coll Cardiol , vol.60 , pp. 1249-1256
    • Ho, J.E.1    Liu, C.2    Lyass, A.3
  • 7
    • 78651387589 scopus 로고    scopus 로고
    • Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
    • PID: 21189092
    • De Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60–8.
    • (2011) Ann Med , vol.43 , pp. 60-68
    • De Boer, R.A.1    Lok, D.J.2    Jaarsma, T.3
  • 8
    • 84896902187 scopus 로고    scopus 로고
    • The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure
    • COI: 1:CAS:528:DC%2BC2cXks1GmtLw%3D, PID: 24606321
    • Meijers WC, van der Velde AR, de Boer RA. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure. Expert Rev Mol Diagn. 2014;14:257–66.
    • (2014) Expert Rev Mol Diagn , vol.14 , pp. 257-266
    • Meijers, W.C.1    van der Velde, A.R.2    de Boer, R.A.3
  • 9
    • 84897017376 scopus 로고    scopus 로고
    • Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments
    • COI: 1:CAS:528:DC%2BC2cXnslart78%3D, PID: 24445238
    • Gaze DC, Prante C, Dreier J, et al. Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments. Clin Chem Lab Med. 2014;52:919–26.
    • (2014) Clin Chem Lab Med , vol.52 , pp. 919-926
    • Gaze, D.C.1    Prante, C.2    Dreier, J.3
  • 10
    • 84899566706 scopus 로고    scopus 로고
    • Using galectin-3 to reduce heart failure rehospitalization
    • COI: 1:CAS:528:DC%2BC2cXmvV2js7c%3D, PID: 24762249
    • Xue Y, Maisel A, Peacock WF. Using galectin-3 to reduce heart failure rehospitalization. Future Cardiol. 2014;10:221–7.
    • (2014) Future Cardiol , vol.10 , pp. 221-227
    • Xue, Y.1    Maisel, A.2    Peacock, W.F.3
  • 11
    • 84895148258 scopus 로고    scopus 로고
    • Shah RV, Januzzi JL, Jr. Soluble ST2 and galectin-3 in heart failure. Clin Lab Med. 2014;34:87–97, vi–vii
    • Shah RV, Januzzi JL, Jr. Soluble ST2 and galectin-3 in heart failure. Clin Lab Med. 2014;34:87–97, vi–vii.
  • 12
    • 84902298336 scopus 로고    scopus 로고
    • Comprehensive review of the prognostic value of galectin-3 in heart failure
    • PID: 24407048
    • Coburn E, Frishman W. Comprehensive review of the prognostic value of galectin-3 in heart failure. Cardiol Rev. 2014;22:171–5.
    • (2014) Cardiol Rev , vol.22 , pp. 171-175
    • Coburn, E.1    Frishman, W.2
  • 13
    • 84886393828 scopus 로고    scopus 로고
    • Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure
    • PID: 24090952
    • Hrynchyshyn N, Jourdain P, Desnos M, Diebold B, Funck F. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch Cardiovasc Dis. 2013;106:541–6.
    • (2013) Arch Cardiovasc Dis , vol.106 , pp. 541-546
    • Hrynchyshyn, N.1    Jourdain, P.2    Desnos, M.3    Diebold, B.4    Funck, F.5
  • 14
    • 84895099043 scopus 로고    scopus 로고
    • Jarolim P. Overview of cardiac markers in heart disease. Clin Lab Med. 2014;34:1–14, xi
    • Jarolim P. Overview of cardiac markers in heart disease. Clin Lab Med. 2014;34:1–14, xi.
  • 15
    • 84893065828 scopus 로고    scopus 로고
    • Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers
    • COI: 1:CAS:528:DC%2BC2cXhs1Ggtrs%3D, PID: 24410541
    • Lippi G, Cervellin G. Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers. Crit Rev Clin Lab Sci. 2014;51:13–29.
    • (2014) Crit Rev Clin Lab Sci , vol.51 , pp. 13-29
    • Lippi, G.1    Cervellin, G.2
  • 17
    • 84896933305 scopus 로고    scopus 로고
    • Plasma galectin 3 and heart failure risk in the Physicians’ Health Study
    • COI: 1:CAS:528:DC%2BC2cXpvVWmsLg%3D, PID: 24464746
    • Djousse L, Matsumoto C, Petrone A, Weir NL, Tsai MY, Gaziano JM. Plasma galectin 3 and heart failure risk in the Physicians’ Health Study. Eur J Heart Fail. 2014;16:350–4.
    • (2014) Eur J Heart Fail , vol.16 , pp. 350-354
    • Djousse, L.1    Matsumoto, C.2    Petrone, A.3    Weir, N.L.4    Tsai, M.Y.5    Gaziano, J.M.6
  • 18
    • 77954658143 scopus 로고    scopus 로고
    • Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study
    • COI: 1:CAS:528:DC%2BC3cXlt1Wqs74%3D, PID: 20130888
    • Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99:323–8.
    • (2010) Clin Res Cardiol , vol.99 , pp. 323-328
    • Lok, D.J.1    Van Der Meer, P.2    de la Porte, P.W.3
  • 19
    • 79960555230 scopus 로고    scopus 로고
    • Galectin-3 in heart failure: high levels are associated with all-cause mortality
    • PID: 21641051
    • Ueland T, Aukrust P, Broch K, et al. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol. 2011;150:361–4.
    • (2011) Int J Cardiol , vol.150 , pp. 361-364
    • Ueland, T.1    Aukrust, P.2    Broch, K.3
  • 20
    • 79960350455 scopus 로고    scopus 로고
    • Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival
    • COI: 1:CAS:528:DC%2BC3MXptVWjsrw%3D, PID: 21600537
    • Tang WH, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011;108:385–90.
    • (2011) Am J Cardiol , vol.108 , pp. 385-390
    • Tang, W.H.1    Shrestha, K.2    Shao, Z.3
  • 21
    • 84876134473 scopus 로고    scopus 로고
    • Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure
    • COI: 1:CAS:528:DC%2BC3sXhslaqtr0%3D, PID: 22886030
    • Lok DJ, Lok SI, Bruggink-Andre de la Porte PW, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013;102:103–10.
    • (2013) Clin Res Cardiol , vol.102 , pp. 103-110
    • Lok, D.J.1    Lok, S.I.2    Bruggink-Andre de la Porte, P.W.3
  • 22
    • 84859639923 scopus 로고    scopus 로고
    • Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study
    • COI: 1:CAS:528:DC%2BC38XjsVCrtrc%3D, PID: 22016505
    • Felker GM, Fiuzat M, Shaw LK, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail. 2012;5:72–8.
    • (2012) Circ Heart Fail , vol.5 , pp. 72-78
    • Felker, G.M.1    Fiuzat, M.2    Shaw, L.K.3
  • 23
    • 84878544017 scopus 로고    scopus 로고
    • Predictive value of plasma galectin-3 in patients with chronic heart failure
    • COI: 1:CAS:528:DC%2BC3sXjslWgsr4%3D, PID: 23661512
    • Chen K, Jiang RJ, Wang CQ, et al. Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci. 2013;17:1005–11.
    • (2013) Eur Rev Med Pharmacol Sci , vol.17 , pp. 1005-1011
    • Chen, K.1    Jiang, R.J.2    Wang, C.Q.3
  • 24
    • 77955463871 scopus 로고    scopus 로고
    • Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure
    • COI: 1:CAS:528:DC%2BC3cXpsFOqs7c%3D, PID: 20525986
    • Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12:826–32.
    • (2010) Eur J Heart Fail , vol.12 , pp. 826-832
    • Shah, R.V.1    Chen-Tournoux, A.A.2    Picard, M.H.3    van Kimmenade, R.R.4    Januzzi, J.L.5
  • 25
    • 20144388239 scopus 로고    scopus 로고
    • The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study
    • COI: 1:CAS:528:DC%2BD2MXjtlWjurs%3D, PID: 15820160
    • Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948–54.
    • (2005) Am J Cardiol , vol.95 , pp. 948-954
    • Januzzi, J.L.1    Camargo, C.A.2    Anwaruddin, S.3
  • 26
    • 84870482586 scopus 로고    scopus 로고
    • Galectin 3 complements BNP in risk stratification in acute heart failure
    • COI: 1:CAS:528:DC%2BC38XhsleltbfO, PID: 22998064
    • Fermann GJ, Lindsell CJ, Storrow AB, et al. Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers. 2012;17:706–13.
    • (2012) Biomarkers , vol.17 , pp. 706-713
    • Fermann, G.J.1    Lindsell, C.J.2    Storrow, A.B.3
  • 27
    • 39549118139 scopus 로고    scopus 로고
    • Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH)
    • PID: 18268174
    • Jaarsma T, van der Wal MH, Lesman-Leegte I, et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med. 2008;168:316–24.
    • (2008) Arch Intern Med , vol.168 , pp. 316-324
    • Jaarsma, T.1    van der Wal, M.H.2    Lesman-Leegte, I.3
  • 28
    • 84887625229 scopus 로고    scopus 로고
    • Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction
    • PID: 24207066
    • Carrasco-Sanchez FJ, Aramburu-Bodas O, Salamanca-Bautista P, et al. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol. 2013;169:177–82.
    • (2013) Int J Cardiol , vol.169 , pp. 177-182
    • Carrasco-Sanchez, F.J.1    Aramburu-Bodas, O.2    Salamanca-Bautista, P.3
  • 29
    • 84877246724 scopus 로고    scopus 로고
    • Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH
    • PID: 23395934
    • Van der Velde AR, Gullestad L, Ueland T, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6:219–26.
    • (2013) Circ Heart Fail , vol.6 , pp. 219-226
    • Van der Velde, A.R.1    Gullestad, L.2    Ueland, T.3
  • 30
    • 84870300941 scopus 로고    scopus 로고
    • The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
    • COI: 1:CAS:528:DC%2BC38XhsF2htr3F, PID: 23194488
    • Gullestad L, Ueland T, Kjekshus J, et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J. 2012;164:878–83.
    • (2012) Am Heart J , vol.164 , pp. 878-883
    • Gullestad, L.1    Ueland, T.2    Kjekshus, J.3
  • 31
    • 84885044150 scopus 로고    scopus 로고
    • Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study
    • COI: 1:CAS:528:DC%2BC3sXhsFyksbrN, PID: 23666680
    • Motiwala SR, Szymonifka J, Belcher A, et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail. 2013;15:1157–63.
    • (2013) Eur J Heart Fail , vol.15 , pp. 1157-1163
    • Motiwala, S.R.1    Szymonifka, J.2    Belcher, A.3
  • 32
    • 84877106997 scopus 로고    scopus 로고
    • Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT
    • COI: 1:CAS:528:DC%2BC3sXmtlequ7w%3D, PID: 23291728
    • Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail. 2013;15:511–8.
    • (2013) Eur J Heart Fail , vol.15 , pp. 511-518
    • Anand, I.S.1    Rector, T.S.2    Kuskowski, M.3    Adourian, A.4    Muntendam, P.5    Cohn, J.N.6
  • 33
    • 84880512915 scopus 로고    scopus 로고
    • Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure
    • PID: 23316284
    • Gopal DM, Kommineni M, Ayalon N, et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc. 2012;1:e000760. doi:10.1161/JAHA.112.
    • (2012) J Am Heart Assoc , vol.1 , pp. e000760
    • Gopal, D.M.1    Kommineni, M.2    Ayalon, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.